Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lactobacillus brevis CD2 in Chronic Periodontitis
NCT02390687Phase 3Completed
- Start
- Apr 2015
- Primary completion
- Sep 2016
- Modality
- Yeast Strains, Defined Consortia, Bacterial Strains
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of lactobacillus brevis cd2 in chronic periodontitis (2 arms). Primary endpoint: Improvement in Periodontal Clinical indices at 8 weeks. Started Apr 2015; status: completed.
02
Drugs
lactobacillus brevis cd2
03
Conditions
chronic periodontitis
Beyond the preview
Go deeper on NCT02390687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02390687.